IRIS
DIGIACOMO, GRAZIANA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 897
EU - Europa 760
AS - Asia 267
AF - Africa 11
SA - Sud America 3
OC - Oceania 1
Totale 1.939
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 894
IT - Italia 355
CN - Cina 154
IE - Irlanda 154
SE - Svezia 102
SG - Singapore 75
DE - Germania 38
BE - Belgio 24
FR - Francia 20
IN - India 16
CI - Costa d'Avorio 11
FI - Finlandia 10
AT - Austria 9
TR - Turchia 9
GB - Regno Unito 8
CZ - Repubblica Ceca 7
NL - Olanda 7
UA - Ucraina 7
VN - Vietnam 6
RO - Romania 5
AR - Argentina 3
CA - Canada 3
CH - Svizzera 3
JP - Giappone 3
LT - Lituania 3
MK - Macedonia 2
PK - Pakistan 2
ES - Italia 1
HR - Croazia 1
HU - Ungheria 1
IR - Iran 1
KR - Corea 1
LU - Lussemburgo 1
NZ - Nuova Zelanda 1
PL - Polonia 1
SI - Slovenia 1
Totale 1.939
Salva come PNG Salva come JPEG
Città #
Ann Arbor 234
Dublin 154
Chandler 148
Parma 75
Singapore 51
Ashburn 48
Boardman 46
Shanghai 44
Dearborn 42
Milan 28
Modena 22
Nanjing 21
Princeton 21
New York 20
Chicago 19
Redmond 17
Bremen 16
Los Angeles 15
Beijing 12
Wayne 12
Abidjan 11
Helsinki 10
Wilmington 10
Izmir 9
San Mateo 9
Shenyang 9
Vienna 9
Des Moines 8
Jinan 8
Reggio Emilia 8
Verona 8
Woodbridge 8
Amsterdam 7
Binche 7
Brussels 7
Rome 7
Dong Ket 6
Follonica 6
Fremont 6
Leuven 6
Marseille 6
Nanchang 6
Seattle 6
Bologna 5
Hebei 5
Munich 5
Casalgrande 4
Florence 4
Hefei 4
London 4
Mons 4
Neviano degli Arduini 4
Norwalk 4
Salsomaggiore Terme 4
Santa Clara 4
Soliera 4
Alvignano 3
Brescia 3
Brno 3
Buenos Aires 3
Castellarano 3
Coimbatore 3
Fairfield 3
Falls Church 3
Fuzhou 3
Grafing 3
Houston 3
Jiaxing 3
Kolkata 3
Kunming 3
Ningbo 3
Prata Di Pordenone 3
Pune 3
Rubiera 3
Savignano sul Rubicone 3
Taiyuan 3
Tianjin 3
Trento 3
Augusta 2
Bergamo 2
Brusaporto 2
Campi Bisenzio 2
Carpenedolo 2
Frankfurt am Main 2
Galatina 2
Guangzhou 2
Haikou 2
Jacksonville 2
Karak 2
Kaunas 2
Leawood 2
Maranello 2
Monmouth Junction 2
Montegaldella 2
Montreal 2
Mumbai 2
Múggia 2
Paris 2
Pesaro 2
Phoenix 2
Totale 1.387
Salva come PNG Salva come JPEG
Nome #
Balancing reactivity and antitumor activity: heteroarylthioacetamide derivatives as potent and time-dependent inhibitors of EGFR 206
Third generation EGFR inhibitor osimertinib combined with pemetrexed or cisplatin exerts long-lasting anti-tumor effect in EGFR-mutated pre-clinical models of NSCLC 123
Efficacy of the cdk4/6 dual inhibitor abemaciclib in egfr-mutated nsclc cell lines with different resistance mechanisms to osimertinib 122
Pemetrexed enhances membrane PD-L1 expression and potentiates T cell-mediated cytotoxicity by anti-PD-L1 antibody therapy in non-small-cell lung cancer 105
Enhancement of the anti-tumor activity of FGFR1 inhibition in squamous cell lung cancer by targeting downstream signaling involved in glucose metabolism. 92
Dual inhibition of CDK4/6 and PI3K/AKT/mTOR signaling impairs energy metabolism in MPM cancer cells 90
Combined Inhibition of CDK4/6 and PI3K/AKT/mTOR Pathways Induces a Synergistic Anti-Tumor Effect in Malignant Pleural Mesothelioma Cells. 87
Enhanced efficacy of AKT and FAK kinase combined inhibition in squamous cell lung carcinomas with stable reduction in PTEN 76
CDK4/6 inhibitors improve the anti-tumor efficacy of lenvatinib in hepatocarcinoma cells 72
Pre-treatment with the CDK4/6 inhibitor palbociclib improves the efficacy of paclitaxel in TNBC cells 71
Targeting metabolic adaptive responses induced by glucose starvation inhibits cell proliferation and enhances cell death in osimertinib-resistant non-small cell lung cancer (NSCLC) cell lines 70
CDK4/6 Inhibition Enhances the Efficacy of Standard Chemotherapy Treatment in Malignant Pleural Mesothelioma Cells 68
The anti-tumor efficacy of CDK4/6 inhibition is enhanced by the combination with PI3K/AKT/mTOR inhibitors through impairment of glucose metabolism in TNBC cells 64
Acquired BRAF G469A Mutation as a Resistance Mechanism to First-Line Osimertinib Treatment in NSCLC Cell Lines Harboring an EGFR Exon 19 Deletion 63
Simultaneous Combination of the CDK4/6 Inhibitor Palbociclib With Regorafenib Induces Enhanced Anti-tumor Effects in Hepatocarcinoma Cell Lines 62
Overcoming Palbociclib Resistance by Combined Treatment with PI3K/AKT/mTOR Inhibitors in Mesothelioma Cells 62
PD-L1 level is up-regulated in NSCLC cells after pemetrexed treatment 57
Biological hallmarks and new therapeutic approaches for the treatment of pdac 54
PD-L1 OVEREXPRESSION INDUCES ANGIOGENIC CYTOKINE SECRETION AND ENDOTHELIAL CELL MIGRATION VIA STAT SIGNALLING. 53
INCREASED SOLUBLE AND MEMBRANE-BOUND PD-L1 EXPRESSION IN NSCLC CELL LINES TREATED WITH PEMETREXED 53
PD-L1 overexpression induces STAT signaling and promotes the secretion of pro-angiogenic cytokines in non-small cell lung cancer (NSCLC) 52
Trastuzumab emtansine delays and overcomes resistance to the third-generation EGFR-TKI osimertinib in NSCLC EGFR mutated cell lines 50
Chromatin-associated CSF-1R binds to the promoter of proliferation-related genes in breast cancer cells 43
Fibronectin induces macrophage migration through a SFK-FAK/CSF-1R pathway 42
It Takes Two to Tango: Potential Prognostic Impact of Circulating TGF-Beta and PD-L1 in Pancreatic Cancer 40
Circulating TGF-Beta and PD-L1 in Pancreatic Cancer 34
PTEN Alterations as a Potential Mechanism for Tumor Cell Escape from PD-1/PD-L1 Inhibition 32
Prostaglandin E2 transactivates the colony-stimulating factor-1 receptor and synergizes with Colony-stimulating factor-1 in the induction of macrophage migration via the mitogen-activated protein kinase ERK1/2 31
State of the art and perspectives in pediatric hepatocellular carcinoma 27
Role of Cytokines and Other Soluble Factors in Tumor Development: Rationale for New Therapeutic Strategies 4
Totale 2.005
Salva come PNG Salva come JPEG
Categoria #
all - tutte 7.633
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 7.633
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020249 0 0 0 11 17 48 56 15 30 39 18 15
2020/2021256 8 14 13 31 25 14 21 27 28 14 28 33
2021/2022176 22 13 24 8 3 3 28 4 11 8 8 44
2022/2023619 44 56 45 39 48 58 12 60 198 6 36 17
2023/2024390 14 23 21 14 48 56 33 25 12 32 55 57
2024/2025152 38 40 60 14 0 0 0 0 0 0 0 0
Totale 2.005